Breaking News
Get 40% Off 0
☕ Buy the dip? After losing 17%, Starbucks sees an estimated 20% upside. See the top Undervalued stocks! Unlock list
Close

Kura Oncology Inc (KURA)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Kura Oncology Inc's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
20.63 +0.04    +0.19%
03/05 - Closed. Currency in USD ( Disclaimer )
After Hours
20.63
0.00
0.00%
21:20:00 - Real-time Data
  • Volume: 604,727
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 20.26 - 21.25
Type:  Equity
Market:  United States
Kura Oncology Inc 20.63 +0.04 +0.19%

Kura Oncology Inc Company Profile

 
Read the Kura Oncology Inc company profile to learn more about the business and the management team. View Kura Oncology Inc facts about employee data, company products and services, and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

142

Equity Type

ORD

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Contact Information

Address 12730 High Bluff Drive Suite 400
San Diego, 92130
United States
Phone 858 500 8800
Fax -

Top Executives

Name Age Since Title
Kevan M. Shokat - - Chairman of the Scientific Advisory Board
Faheem Hasnain 64 2015 Lead Independent Director
Thomas R. Malley 53 2015 Independent Director
Neal Rosen 72 - Scientific Advisor
Frank McCormick 72 - Scientific Advisor
Mary T. Szela 58 2018 Independent Director
Troy Edward Wilson 53 2015 Chairman, CEO, President & Principal Financial Officer
Carol A. Schafer 58 2021 Independent Director
Steven M. Horwitz - - Clinical Advisor
Diane L. Parks 71 2019 Independent Director
Josep Tabernero - - Clinical Advisor
Daniel Douglas Von Hoff 75 - Clinical Advisor
Alan Houghton - - Clinical Advisor
Helen Louise Collins 60 2021 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

KURA Price Commentary

Write your thoughts about Kura Oncology Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email